MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
äŒæ¥ã³ãŒãMDXG
äŒç€ŸåMiMedx Group Inc
äžå Žæ¥Aug 20, 2007
æé«çµå¶è²¬ä»»è
ãCEOãCapper (Joseph H)
åŸæ¥å¡æ°837
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Aug 20
æ¬ç€Ÿæåšå°1775 W Oak Commons Court, Ne
éœåžMARIETTA
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·30062
é»è©±çªå·17706519100
ãŠã§ããµã€ãhttps://mimedx.com/
äŒæ¥ã³ãŒãMDXG
äžå Žæ¥Aug 20, 2007
æé«çµå¶è²¬ä»»è
ãCEOãCapper (Joseph H)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã